In the most recent World Health Organization (WHO) CHB treatment guidelines released in March 2024, the WHO recommends treatment of CHB patients who have evidence of significant fibrosis, an HBV viral load of greater than 2000 IU/mL with elevated alanine transaminase (ALT) levels, or presence of co-infections such as HIV [11]. This evidence concerns the gene GPT and coinfection.